

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Balance Sheet as at March 31, 2024

Particulars	Note No.	CAD
		As at March 31 2024
ASSETS:		
Non-Current Assets:		
Property, Plant and Equipment	1	2,333
Deferred Tax Assets [Net]	2	26,935
Total		29,268
EQUITY AND LIABILITIES:		
Equity:		
Equity Share Capital		-
Other Equity	3	(74,020)
		(74,020)
Current Liabilities:		
Other Current Liabilities	4	103,288
Total		29,268

Statement of Profit and Loss for the period ended March 31, 2024

Particulars	Note No.	CAD
		For the period from 06/09/2023 to 31/03/2024
Revenue from Operations		-
Other Income		-
Total Income		-
EXPENSES:		
Employee Benefits Expense	5	29,003
Depreciation, Amortisation and Impairment expense	1	67
Other Expenses	6	71,885
Total Expenses		100,955
Loss before Tax		(100,955)
Less: Tax Expense:		
Current Tax		-
Deferred Tax	2	(26,935)
		(26,935)
Loss for the period		(74,020)

For and on behalf of the Board

Sd/-

Director

Dated : May 15, 2024

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]

Notes to the Financial Statements

Note: 1-Property, Plant & Equipment and Intangible Assets:	CAD
	As at March 31
	2024
Office Equipment:	
Gross Block:	
As at September 06, 2023	-
Additions	2,400
Disposals	-
As at March 31, 2024	2,400
Depreciation and Impairment:	
As at September 06, 2023	-
Depreciation for the year	67
Disposals	-
As at March 31, 2024	67
Net Block:	
As at September 06, 2023	-
As at March 31, 2024	2,333
Note: 2-Deferred Tax:	
Deferred Tax Assets:	
Others	26,935
Net Deferred Tax Liabilities [Assets]	26,935
Note: 3-Other Equity-Continued:	
Retained Earnings:	
Balance as per last Balance Sheet	-
Add : [Loss] for the year	(74,020)
Total	(74,020)
Note: 4-Other Current Liabilities:	
Others	103,288
Total	103,288
	CAD
	For the period from 06/09/2023 to 31/03/2024
Note: 5-Employee Benefits Expense:	
Salaries and wages	29,003
Total	29,003
Note: 6-Other Expenses:	
Legal and Professional Fees	64,175
Miscellaneous Expenses	7,710
Total	71,885

ZYDUS PHARMACEUTICALS CANADA INC [CANADA]
Cash Flow Statement for the period ended March 31, 2024

Particulars	CAD
	For the period from 06/09/2023 to 31/03/2024
A Cash flows from operating activities:	
Loss before tax	(100,955)
Adjustments for:	
Depreciation, Impairment and Amortisation expenses	67
Total	67
Operating loss before working capital changes	(100,888)
Adjustments for:	
Increase in other current liabilities	103,288
Total	103,288
Net cash from operating activities	2,400
B Cash flows from investing activities:	
Purchase of Property, Plant and Equipment	-
Net cash [used in] investing activities	-
C Cash flows from financing activities:	
Net cash from / [used in] financing activities	-
Net Increase in cash and cash equivalents	2,400
Cash and cash equivalents at the beginning of the period	-
Cash and cash equivalents at the end of the period	2,400

Notes to the Cash Flow Statement

1 All figures in brackets are outflows.

For and on behalf of the Board

Sd/-

Director
Dated : May 15, 2024